{"brief_title": "Multicenter Trial for Adults With Partial Seizures", "brief_summary": "To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.", "detailed_description": "A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.", "condition": "Epilepsy", "intervention_type": "Drug", "intervention_name": "Talampanel", "description": "Non-enzyme-inducing TLP 25mg TID", "arm_group_label": "5", "criteria": "Inclusion Criteria: - must weigh greater than or equal to 40kg - Patients must have diagnosis of partial seizures - At least 3 observable partial seizures a month - Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs. Exclusion: - Patients on Valproic acid, and Felbamate", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00034814.xml"}